pirfenidone has been researched along with Acute Disease in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Dawra, RK; Dudeja, V; George, J; Giri, B; Iyer, S; Jain, T; Palathingal Bava, E; Sahay, P; Saluja, AK; Sharma, P; Tarique, M; Vaish, U | 1 |
| Leslie, K; Morell, F; Raghu, G; Vasakova, M; Walsh, S | 1 |
| Abe, M; Ichimura, Y; Ikari, J; Matsumura, A; Matsumura, T; Suzuki, K; Tatsumi, K; Terada, J; Tsushima, K; Yamagishi, K | 1 |
| El-Agamy, DS; El-Kashef, DH; Shaaban, AA | 1 |
| Iwata, T; Mizobuchi, T; Nagato, K; Nakajima, T; Nakatani, Y; Ota, S; Suzuki, H; Tagawa, T; Yoshida, S; Yoshino, I | 1 |
| Azuma, A; Ebina, M; Kondoh, Y; Kudoh, S; Nakata, K; Nukiwa, T; Ogura, T; Suga, M; Sugiyama, Y; Taguchi, Y; Takahashi, H; Taniguchi, H | 1 |
| Brien, JF; Card, JW; Margolin, SB; Massey, TE; Racz, WJ | 1 |
| Boichot, E; Corbel, M; Germain, N; Lagente, V; Lanchou, J; Malledant, Y | 1 |
8 other study(ies) available for pirfenidone and Acute Disease
| Article | Year |
|---|---|
Pirfenidone ameliorates chronic pancreatitis in mouse models through immune and cytokine modulation.
Topics: Acute Disease; Animals; Arginine; Ceruletide; Collagen; Cytokines; Disease Models, Animal; Fibrosis; Humans; Mice; Pancreatitis, Chronic; Pyridones | 2022 |
Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management.
Topics: Acute Disease; Adrenal Cortex Hormones; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents, Non-Steroidal; Antigens; Bronchoalveolar Lavage Fluid; Chronic Disease; Disease Progression; Enzyme Inhibitors; Humans; Immunoglobulin G; Immunologic Factors; Immunosuppressive Agents; Indoles; Lung; Lung Transplantation; Pyridones; Tomography, X-Ray Computed | 2017 |
The effects of pirfenidone in patients with an acute exacerbation of interstitial pneumonia.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Japan; Male; Prognosis; Pyridones; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Necrosis Factor-alpha | 2018 |
Protective role of pirfenidone against experimentally-induced pancreatitis.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Apoptosis; Arginine; Cytokines; Disease Models, Animal; Male; Mice; Oxidative Stress; Pancreas; Pancreatic Function Tests; Pancreatitis; Pyridones | 2019 |
Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Disease Progression; Feasibility Studies; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Middle Aged; Perioperative Care; Postoperative Complications; Pyridones; Retrospective Studies; Treatment Outcome | 2015 |
Risk factors for acute exacerbation of idiopathic pulmonary fibrosis--Extended analysis of pirfenidone trial in Japan.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase III as Topic; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Multivariate Analysis; Oxygen Consumption; Proportional Hazards Models; Pulmonary Alveoli; Pyridones; Risk Factors; Vital Capacity | 2015 |
Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity.
Topics: Acute Disease; Amiodarone; Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Cricetinae; Disease Models, Animal; Hydroxyproline; Male; Membrane Potentials; Mitochondria; Oxygen Consumption; Pulmonary Fibrosis; Pyridones; RNA, Messenger; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2003 |
Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bronchoalveolar Lavage Fluid; Cell Count; Inflammation Mediators; Lipopolysaccharides; Lung; Lung Diseases; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, Inbred BALB C; Phenylalanine; Pyridones; Thiophenes; Tissue Inhibitor of Metalloproteinases; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2001 |